ONYX-411, a conditionally replicative oncolytic adenovirus, induces cell death in anaplastic thyroid carcinoma cell lines and suppresses the growth of xenograft tumors in nude mice

Cancer Gene Therapy

Volumn 15, Issue 11, 2008, Pages 750-757

  Reddi, H V ^a   Madde, P ^a   Reichert Eberhardt, A J ^a   Galanis, E C ^a   Copland, J A ^b   McIver, B ^a   Grebe, S K G ^a   Eberhardt, N L ^a  

^a MAYO CLINIC   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Anaplastic thyroid carcinoma; Novel therapeutic agent; ONYX 411; Retinoblastoma dysfunction

Indexed keywords

COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; ONCOLYTIC ADENOVIRUS; ONYX 411; UNCLASSIFIED DRUG;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL DEATH; CELL KILLING; CELL LINE; CONTROLLED STUDY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; RETINOBLASTOMA; THYROID CANCER; THYROID CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; THYROID NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

EID: 53549107470     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2008.44     Document Type: Article

References (27)

1. http://www.cancer.org/docroot/stt/stt_0.asp.
2. Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol 2006; 13: 453-464.
3. Haigh PI. Anaplastic thyroid carcinoma. Curr Treat Options Oncol 2000; 1: 353-357.
4. Copland JA, Marlow LA, Kurakata S, Fujiwara K, Wong AK, Kreinest PA et al. Novel high-affinity PPAR-gamma agonist alone and in combination with paclitaxel inhibits human anaplastic thyroid carcinoma tumor growth via p21WAF1/CIP1. Oncogene 2006; 25: 2304-2317.
5. Elisei R, Vivaldi A, Ciampi R, Faviana P, Basolo F, Santini F et al. Treatment with drugs able to reduce iodine efflux significantly increases the intracellular retention time in thyroid cancer cells stably transfected with sodium iodide symporter complementary deoxyribonucleic acid. J Clin Endocrinol Metab 2006; 91: 2389-2395.
6. Santarpia L, El-Naggar AK, Cote GJ, Myers JN, Sherman SI. Phoshatidylinositol 3-kinase/Akt and Ras/Raf-mitogen-activated kinase pathway mutations in anaplastic thyroid cancer. J Clin Endocrinol Metab 2008; 93: 278-284.
7. Saltman B, Singh B, Hedvat CV, Wreesmann VB, Ghossein R. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Surgery 2006; 140: 899-905.
8. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
9. Bartek J, Bartkova J, Lukas J. The retinoblastoma protein pathway in cell cycle control and cancer. Exp Cell Res 1997; 237: 1-6.
10. Anwar F, Emond MJ, Schmidt RA, Hwang HC, Bronner MP. Retinoblastoma expression in thyroid neoplasms. Mod Pathol 2000; 13: 562-569.
11. Volante M, Croce S, Pecchioni C, Papotti M. E2F-1 transcription factor is overexpressed in oxyphilic thyroid tumors. Mod Pathol 2002; 15: 1038-1043.
12. McNeish IA, Bell SJ, Lemoine NR. Gene therapy progress and prospects: cancer gene therapy using tumour suppressor genes. Gene Therapy 2004; 11: 497-503.
13. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007; 254: 178-216.
14. Yu Z, Eisenberg DP, Singh B, Shah JP, Fong Y, Wong RJ. Treatment of aggressive thyroid cancer with an oncolytic herpes virus. Int J Cancer 2004; 112: 525-532.
15. Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. J Clin Endocrinol Metab 2002; 87: 2525-2531.
16. Abbosh PH, Li X, Li L, Gardner TA, Kao C, Nephew KP. A conditionally replicative, Wnt/beta-catenin pathway-based adenovirus therapy for anaplastic thyroid cancer. Cancer Gene Ther 2007; 14: 399-408.
17. Cohen EE, Rudin CM. ONYX-015. Onyx pharmaceuticals. Curr Opin Investig Drugs 2001; 2: 1770-1775.
18. Liu TC, Galanis E, Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007; 4: 101-117.
19. Lam KY, Lo CY, Chan KW, Wan KY. Insular and anaplastic carcinoma of the thyroid: a 45-year comparative study at a single institution and a review of the significance of p53 and p21. Ann Surg 2000; 231: 329-338.
20. Johnson L, Shen A, Boyle L, Kunich J, Pandey K, Lemmon M et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. Cancer Cell 2002; 1: 325-337.
21. Dyson N, Guida P, McCall C, Harlow E. Adenovirus E1A makes two distinct contacts with the retinoblastoma protein. J Virol 1992; 66: 4606-4611.
22. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986; 89: 271-277.
23. Meier O, Greber UF. Adenovirus endocytosis. J Gene Med 2004; 6(Suppl 1): S152-S163.
24. Fueyo J, Alemany R, Gomez-Manzano C, Fuller GN, Khan A, Conrad CA et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652-660.
25. Saito Y, Sunamura M, Motoi F, Abe H, Egawa S, Duda DG et al. Oncolytic replication-competent adenovirus suppresses tumor angiogenesis through preserved E1A region. Cancer Gene Ther 2006; 13: 242-252.
26. Mizukami Y, Kohgo Y, Chung DC. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis. Clin Cancer Res 2007; 13: 5670-5674.
27. Mukhopadhyay D, Datta K. Multiple regulatory pathways of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) expression in tumors. Semin Cancer Biol 2004; 14: 123-130.